Abeona Therapeutics (ABEO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$35.6 million.
- Abeona Therapeutics' Income towards Parent Company fell 1747.33% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 16761.36%. This contributed to the annual value of -$68.4 million for FY2024, which is 4387.95% down from last year.
- According to the latest figures from Q3 2025, Abeona Therapeutics' Income towards Parent Company is -$35.6 million, which was down 1747.33% from $108.8 million recorded in Q2 2025.
- Abeona Therapeutics' Income towards Parent Company's 5-year high stood at $108.8 million during Q2 2025, with a 5-year trough of -$46.7 million in Q4 2021.
- Its 5-year average for Income towards Parent Company is -$10.3 million, with a median of -$15.2 million in 2021.
- As far as peak fluctuations go, Abeona Therapeutics' Income towards Parent Company tumbled by 19485.09% in 2021, and later skyrocketed by 136952.47% in 2025.
- Abeona Therapeutics' Income towards Parent Company (Quarter) stood at -$46.7 million in 2021, then soared by 71.9% to -$13.1 million in 2022, then fell by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then crashed by 100.28% to -$35.6 million in 2025.
- Its last three reported values are -$35.6 million in Q3 2025, $108.8 million for Q2 2025, and -$20.7 million during Q1 2025.